FRANKFURT (Thomson Financial) - Bayer AG. said it started a second phase III
study of the VEGF Trap-Eye injection it is developing with Regeneron
Pharmaceuticals Inc. as a treatment of the neovascular form of age-related
macular degeneration (wet AMD).
As part of the study, Bayer will enrol about 1,200 patients in Europe, Asia
Pacific, Japan and Latin America, the German drug maker said in a statement.
The first phase III study began enrolling patients in August 2007 in the
United States and Canada, it added.
Bayer is trying to show in the trials that VEGT Trap-Eye improves visual
acuity and reduces thickness of the retina, a measure of disease activity, and
that the drug is as good as Genentech Inc.'s Lucentis in fighting wet AMD.
ludwig.burger@thomsonreuters.com
lb/ajb
COPYRIGHT
Copyright Thomson Financial News Limited 2008. All rights reserved.
The copying, republication or redistribution of Thomson Financial News Content,
including by framing or similar means, is expressly prohibited without the prior
written consent of Thomson Financial News.
|